BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32638444)

  • 1. Molecular characteristics and markers of advanced clear cell renal cell carcinoma: Pitfalls due to intratumoral heterogeneity and identification of genetic alterations associated with metastasis.
    Obeng RC; Arnold RS; Ogan K; Master VA; Pattaras JG; Petros JA; Osunkoya AO
    Int J Urol; 2020 Sep; 27(9):790-797. PubMed ID: 32638444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preservation of truncal genomic alterations in clear cell and papillary renal cell carcinomas with sarcomatoid features: An intra- and intertumoral, multifocal fluorescence in situ hybridization analysis reveals limited genetic heterogeneity.
    Sanfrancesco JM; Eble JN; Grignon DJ; Wang M; Zhang S; Sundaram CP; Idrees MT; Pili R; Kouba E; Cheng L
    Mol Carcinog; 2017 Nov; 56(11):2527-2537. PubMed ID: 28667776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential immunohistochemical and molecular profiling of conventional and aggressive components of chromophobe renal cell carcinoma: pitfalls for diagnosis.
    Chen CV; Croom NA; Simko JP; Stohr BA; Chan E
    Hum Pathol; 2022 Jan; 119():85-93. PubMed ID: 34800526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy.
    Singh RR; Murugan P; Patel LR; Voicu H; Yoo SY; Majewski T; Mehrotra M; Wani K; Tannir N; Karam JA; Jonasch E; Wood CG; Creighton CJ; Medeiros LJ; Broaddus RR; Tamboli P; Baggerly KA; Aldape KD; Czerniak B; Luthra R; Sircar K
    Mod Pathol; 2015 Sep; 28(9):1225-35. PubMed ID: 26111976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation.
    Jones TD; Eble JN; Wang M; Maclennan GT; Jain S; Cheng L
    Cancer; 2005 Sep; 104(6):1195-203. PubMed ID: 16047350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Copy Number Alterations in Renal Cell Carcinoma with Sarcomatoid Features.
    Ito T; Pei J; Dulaimi E; Menges C; Abbosh PH; Smaldone MC; Chen DY; Greenberg RE; Kutikov A; Viterbo R; Uzzo RG; Testa JR
    J Urol; 2016 Apr; 195(4 Pt 1):852-8. PubMed ID: 26602888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.
    Serie DJ; Joseph RW; Cheville JC; Ho TH; Parasramka M; Hilton T; Thompson RH; Leibovich BC; Parker AS; Eckel-Passow JE
    Eur Urol; 2017 Jun; 71(6):979-985. PubMed ID: 27899233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
    Tennenbaum DM; Manley BJ; Zabor E; Becerra MF; Carlo MI; Casuscelli J; Redzematovic A; Khan N; Arcila ME; Voss MH; Feldman DR; Motzer RJ; Benfante NE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA
    Urol Oncol; 2017 Aug; 35(8):532.e7-532.e13. PubMed ID: 28408295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
    Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
    Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma: A Clinicopathologic Study of 37 Cases From a Single Institution.
    Dhakal HP; McKenney JK; Khor LY; Reynolds JP; Magi-Galluzzi C; Przybycin CG
    Am J Surg Pathol; 2016 Feb; 40(2):141-54. PubMed ID: 26752401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma.
    Mytsyk Y; Borys Y; Tumanovska L; Stroy D; Kucher A; Gazdikova K; Rodrigo L; Kruzliak P; Prosecky R; Urdzik P; Dosenko V
    Clin Exp Med; 2019 Nov; 19(4):515-524. PubMed ID: 31440867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Sarcomatoid Renal Cell Carcinoma with Clear Cell Papillary-Like Primary Tumor and Lymph Node Metastasis: A Diagnostic Conundrum.
    Demko N; Glennon KI; Arseneault M; Lach K; Nishimura T; Tanguay S; Riazalhosseini Y; Brimo F
    Int J Surg Pathol; 2023 Aug; 31(5):890-895. PubMed ID: 36562104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial Comment from Dr Tsuzuki to Molecular characteristics and markers of advanced clear cell renal cell carcinoma: Pitfalls due to intratumoral heterogeneity and identification of genetic alterations associated with metastasis.
    Tsuzuki T
    Int J Urol; 2020 Sep; 27(9):798-799. PubMed ID: 32767498
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial Comment from Dr Kato to Molecular characteristics and markers of advanced clear cell renal cell carcinoma: Pitfalls due to intratumoral heterogeneity and identification of genetic alterations associated with metastasis.
    Kato T
    Int J Urol; 2020 Sep; 27(9):797-798. PubMed ID: 32741002
    [No Abstract]   [Full Text] [Related]  

  • 17. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.
    Malouf GG; Ali SM; Wang K; Balasubramanian S; Ross JS; Miller VA; Stephens PJ; Khayat D; Pal SK; Su X; Sircar K; Tamboli P; Jonasch E; Tannir NM; Wood CG; Karam JA
    Eur Urol; 2016 Aug; 70(2):348-57. PubMed ID: 26895810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
    Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
    Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
    [No Abstract]   [Full Text] [Related]  

  • 19. Loss of BAP1 protein expression in the first metastatic site predicts prognosis in patients with clear cell renal cell carcinoma.
    Miura Y; Inoshita N; Ikeda M; Miyama Y; Oki R; Oka S; Kondoh C; Ozaki Y; Tanabe Y; Kurosawa K; Urakami S; Kohno T; Okaneya T; Takano T
    Urol Oncol; 2017 Jun; 35(6):386-391. PubMed ID: 28284891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3.
    Boorjian S
    Urol Oncol; 2014 Aug; 32(6):934-5. PubMed ID: 25087671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.